Bovie Medical Corporation (the “Company”)
(Amex: BVX), a manufacturer and marketer of electrosurgical products,
today announced a CE Mark for its Modular Ergonomic Instruments (MEG
laparoscopic line), allowing the MEG Laparoscopic line to be marketed
throughout the European Union.
The patent-pending modular forceps and accessories are designed to
provide surgeons added comfort while reducing per-procedure costs
through the reduction of inventory and obsolescence. The proprietary
instruments offer a simpler assembly process for laparoscopic
procedures. The MEG Laparoscopic line is directed towards the
laparoscopic market with estimated worldwide size exceeding $425
million. The Company anticipates shipments of the instrument line to
commence during the second quarter of 2008.
Mr. Johan Segers of Antwerp, Belgium, was appointed Bovie’s
Director of Sales and Marketing for Europe and the Middle East. Mr.
Segers has a Masters Degree in Health Care Sciences from the University
of Brussels and has over 25 years of successful distribution experience
with US, Israeli and European medical companies. Mr. Segers is in the
process of recruiting and training a network of talented distributors
throughout the EU and Middle East markets as well as retaining key
surgeon opinion leaders for the MEG Laparoscopic line of instruments as
well as other Bovie products.
Andrew Makrides, president of Bovie Medical, stated, “The
CE Mark confirms compliance with essential requirements of the European
Medical Devices Directive and represents a product development milestone
for our company. We look to build on this success with additional new
products coming to market in the near future.”
This document may contain some forward looking statements, particularly
regarding operational prospects in 2008 and beyond, which involve a
number of risks and uncertainties that could cause actual results to
differ materially. These risks are listed from time to time in the
Company’s SEC filings. www.boviemedical.com
|